Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

handshake

Sanofi to acquire Blueprint, advancing therapy for rare immunological diseases

June 3, 2025 Mergers and Acquisitions, Research and Development Blueprint Medicines, Immunology, Rare Diseases, Sanofi, advanced systemic mastocytosis (ASM), indolent systemic mastocytosis (ISM), rare immunological diseases

Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This …
News

New CAR T Vision Coalition and roadmap report to launch at ASCO aims to double patients treated with CAR T-cell therapy by 2030

June 3, 2025 Research and Development American Society of Clinical Oncology, CAR T Vision, CAR T-cell therapy, International Myeloma Foundation, Kite, Leukemia & Lymphoma Society, Oncology, blood cancer

For people living with aggressive blood cancers, CAR T-cell therapy offers hope for a longer, healthier life, and for some, …
News
Press release

Gene Weaver awarded Gates Foundation grant for programmable gene insertion platform

May 30, 2025 Medical Communications, Research and Development Bill and Melinda Gates Foundation, Gene Weaver, Oncology, Pharmacy, Rare Diseases, funding, gene editing

UK-based biotech Gene Weaver has received $515,000 from the Bill and Melinda Gates Foundation to advance its programmable gene insertion technology …
News

Ochre Bio appoints Elaine Sullivan as senior independent non-executive director

May 30, 2025 Research and Development Infections and infestations, Ochre Bio, Oncology, RNA therapeutics, Rare Diseases, appointment, senior independent non-executive director

Ochre Bio has appointed Elaine Sullivan as senior independent non-executive director. She joins the Oxford-based RNA therapeutics company with a …
Appointment
clinical_trials_2

NICE recommends mirikizumab (Omvoh â–¼) for previously treated moderately to severely active Crohn’s disease 1

May 30, 2025 Research and Development Crohn’s disease, Eli Lilly and Company, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency (MHRA)(, NHS England and Wales, National Institute for Health and Care Excellence (NICE), Omvoh, inflammatory bowel disease (IBD), mirikizumab

In the Phase 3 VIVID-1 trial, patients treated with mirikizumab experienced significant improvement in clinical remission and endoscopic response at …
News
Press release

DEBRA Research and Dermaliq Therapeutics collaborate to advance treatment for rare skin disorder

May 29, 2025 Research and Development DEBRA Research, Dermaliq Therapeutics, Dermatology, epidermolysis bullosa, non-profit organisation, skin disorders

Global non-profit organisation, DEBRA Research, and clinical dermatology company, Dermaliq Therapeutics, have announced a collaboration to advance drug development for …
News

Ryvu Therapeutics appoints Justyna Żółtek to management board

May 29, 2025 Medical Communications, Research and Development Oncology, Ryvu Therapeutics, chief people officer, human resources, management board, oncology

Ryvu Therapeutics has promoted Justyna Żółtek, chief people officer, to its management board. The appointment reflects the company’s focus on …
Appointment
clinical_trial_3

Neogap receives approval to administer full dose in cell therapy trial for colorectal cancer

May 28, 2025 Research and Development Neogap, Oncology, Swedish Medical Products Agency, colorectal cancer

Neogap Therapeutics has received regulatory approval from the Swedish Medical Products Agency to administer the full dose of its investigational …
News

UK Researcher Wins Prestigious IBSA Foundation Fellowship for Pioneering Dermatology Study

May 28, 2025 Medical Communications, Research and Development Dermatology, IBSA Foundation Fellowship, Institut Biochimique SA (IBSA), Masami Ando Kuri, Milan Italy, Wellcome Sanger Institute, dermatology

Masami Ando Kuri from the Wellcome Sanger Institute named one of six global winners of the 2024 IBSA Foundation Fellowships. …
News
Press release
lab

The Royal Marsden launches AI radiology platform to revolutionise cancer care

May 27, 2025 Analytical & Laboratory Services, Market & Product Development, Medical Education, Research and Development AI, CARPL.ai., Institute of Cancer Research, NTT DATA, National Institute for Health and Care Research, Oncology, The Royal Marsden, oncology, radiology

The Royal Marsden, a world-leading cancer research centre, has launched a large-scale, AI-powered radiology platform designed to accelerate cancer detection …
News

MC2 Therapeutics appoints Trine Ahlgreen as new CEO

May 27, 2025 Research and Development, Sales and Marketing CEO, Corporate, MC2 Therapeutics, Skin, inflammatory skin conditions

MC2 Therapeutics, a Danish pharma company focused on topical therapies for inflammatory skin conditions, has appointed Trine Ahlgreen as CEO. …
Appointment
clinical_trials_2

Moderna doses first US patient in phase 1 trial of mRNA-4106 for solid tumours

May 23, 2025 Research and Development Moderna, Oncology, START Center for Cancer Research, US

The START Center for Cancer Research has dosed the first US participant in Moderna’s phase 1 clinical trial evaluating mRNA-4106, …
News

NICE recommends treatment for chronic kidney disease, IgA nephropathy

May 23, 2025 Market & Product Development, Medical Communications, Research and Development IgA nephropathy, National Institute for Health and Care Excellence, Nephrology, kidney disease

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Vifor’s FILSPARI (sparsentan) for …
News
blood_test

CHMP issues positive opinion for Blenrep combinations in relapsed/refractory multiple myeloma

May 23, 2025 Market & Product Development, Medical Communications, Research and Development Blenrep, Committee for Medicinal Products for Human USE, European Medicines Agency, Oncology, multiple myeloma

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion …
News
handshake

Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline

May 23, 2025 Mergers and Acquisitions, Research and Development Alzheimer's disease, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies for neurodegenerative diseases. The deal …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025